









Markets
/
Stocks
/
nasdaq-atha
/

Athira Pharma Inc

ATHA

4.150USD

-0.130-3.04%

Market hours （ET）Quotes delayed by 15 min

16.37MMarket Cap

LossP/E TTM



Athira Pharma Inc

4.150

-0.130-3.04%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Athira Pharma Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Athira Pharma Inc's Score

Industry at a Glance

Industry Ranking

273 / 501

Overall Ranking

488 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Hold

Current Rating

5.000

Target Price

+30.55%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Athira Pharma Inc Highlights

StrengthsRisks

Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.

Fairly Valued

The company’s latest PE is -0.27, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.73M shares, decreasing 29.79% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 24.10K shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Athira Pharma Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 6.47, which is lower than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -0.27, which is -58.76% below the recent high of -0.11 and -941.01% above the recent low of -2.80.

Score

Industry at a Glance

Previous score

6.47

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 273/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 6.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Athira Pharma Inc is 5.00, with a high of 5.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Hold

Current Rating

5.000

Target Price

+30.55%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Athira Pharma Inc

ATHA

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 7.42, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 4.63 and the support level at 3.64, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.26

Change

0.16

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.115

Neutral

RSI(14)

66.538

Neutral

STOCH(KDJ)(9,3,3)

76.261

Neutral

ATR(14)

0.260

Low Volatility

CCI(14)

132.930

Buy

Williams %R

24.276

Buy

TRIX(12,20)

1.076

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

4.171

Sell

MA10

4.122

Buy

MA20

3.964

Buy

MA50

2.840

Buy

MA100

1.607

Buy

MA200

0.977

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 43.96%, representing a quarter-over-quarter decrease of 15.26%. The largest institutional shareholder is The Vanguard, holding a total of 153.79K shares, representing 3.90% of shares outstanding, with 3.13% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Perceptive Advisors LLC

540.30K

BML Capital Management LLC

323.07K

+0.94%

Nemean Asset Management, LLC

199.47K

The Vanguard Group, Inc.

Star Investors

153.79K

Propel Bio Management, LLC

149.28K

Simplify Asset Management Inc

149.28K

Tang Capital Management, LLC

60.00K

BofA Global Research (US)

41.62K

+0.01%

Acadian Asset Management LLC

40.55K

-5.38%

BlackRock Institutional Trust Company, N.A.

37.24K

-16.58%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 3.06. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.